at the same time as [1%:0.1%) were, in decreasing order of incidence: acne, exacerbation of psoriasis, eye irritation, and pustular rash. In a 52-week trial, adverse reactions that were reported by >1% of subjects treated with Taclonex Topical Suspension were pruritus (3.6%), psoriasis (2.4%), erythema (2.1%), skin irritation (1.4%), and folliculitis (1.2%). Clinical Trials Conducted in Subjects 18 years and older with Psoriasis on the Body In randomized, multicenter, prospective vehicle- and/or active controlled clinical trials in adult subjects with plaque psoriasis on non-scalp areas, subjects applied study product once daily for 8 weeks. A total of 824 subjects were treated with Taclonex Topical Suspension and the median weekly dose was 22.6 g. There were no adverse reactions that occurred in 1% of subjects treated with Taclonex Topical Suspension and at a rate higher than in subjects treated with vehicle. Other less common adverse reactions (] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturers Perrigo Company Sandoz Inc. Drug Class Topical antipsoriatics Related Drugs topical antipsoriatics calcitriol topical , calcipotriene topical , Taclonex , Dovonex , Calcitrene , Tazorac Plaque Psoriasis Humira , dexamethasone , methylprednisolone , betamethasone topical , Enbrel , Remicade , Otezla , adalimumab , calcipotriene topical , infliximab , etanercept , Cosentyx , More... Psoriasis Humira , methotrexate , cyclosporine , Remicade , adalimumab , infliximab , Stelara , Trexall , Rasuvo , acitretin , Neoral , More... Betamethasone / calcipotriene topical Rating 51 User Reviews 7.4 /10 51 User Reviews 7.4 Rate it! addiction
for that reason Taclonex Topical Suspension idea
EmoticonEmoticon